Edition:
India

People: Intra-Cellular Therapies Inc (ITCI.OQ)

ITCI.OQ on NASDAQ Stock Exchange Global Select Market

12.62USD
1:30am IST
Change (% chg)

$-0.43 (-3.30%)
Prev Close
$13.05
Open
$13.05
Day's High
$13.18
Day's Low
$12.61
Volume
65,832
Avg. Vol
123,307
52-wk High
$23.49
52-wk Low
$10.24

Bardi, John 

Mr. John A. Bardi Senior Vice President - Market Access, Policy and Government Affairs of the company. Mr. Bardi joins ITCI from Otsuka America Pharmaceuticals, Inc where he was initially recruited as Vice President, Market Access, Policy Advocacy, and Government Affairs to build and establish new functions and capabilities to support their products including Abilify®, Abilify Maintena® and Rexulti®. Most recently Mr. Bardi led the Payer & Integrated Delivery Networks Business Development efforts in support of the launch of the first FDA approved Digital Medicine Product. Prior to Otsuka, Mr. Bardi spent 7 years at Bristol-Myers Squibb (BMS) where he served as one of the original members of the US Abilify® Marketing team leading the Payer, Pricing and Advocacy function. In his final years at BMS, Mr. Bardi was Vice President for Market Access leading the function and field based teams in support of BMS' full portfolio of products including Neuroscience, Cardiology, and Oncology. John received his Bachelor of Arts in Public Administration from West Chester University of Pennsylvania and his Masters in Health Services Administration from The George Washington University in Washington, DC.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Lawrence Hineline

2,127,810

Michael Halstead

2,193,200

Mark Neumann

--

Andrew Satlin

2,018,330

Robert Davis

2,128,540

John Bardi

--
As Of  31 Dec 2018